| General Information | |
|---|---|
| ZINC ID/ Molecule Name | ZINC000096937557 |
| Molecular Weight (Da) | 550 |
| SMILES | O=C(CC1CCCC1)NC1CCN(c2ncnc3c2nc(-c2ccccc2Cl)n3-c2ccc(Cl)cc2)CC1 |
| Molecular Formula | C29Cl2N6O1 |
| Action | Antagonist |
| General Information | |
|---|---|
| ZINC ID/ Molecule Name | ZINC000096937557 |
| Molecular Weight (Da) | 550 |
| SMILES | O=C(CC1CCCC1)NC1CCN(c2ncnc3c2nc(-c2ccccc2Cl)n3-c2ccc(Cl)cc2)CC1 |
| Molecular Formula | C29Cl2N6O1 |
| Action | Antagonist |
| Physicochemical Details | |
|---|---|
| ZINC ID/ Molecule Name | ZINC000096937557 |
| Molar Refractivity | 151.259 |
| HBA | 4 |
| HBD | 1 |
| Rotatable Bonds | 6 |
| Heavy Atoms | 38 |
| LogP | 6.447 |
| Activity (Ki) in nM | 575.44 |
| Polar Surface Area (PSA) | 75.94 |
| Pharmacokinetic Properties | |
|---|---|
| ZINC ID/ Molecule Name | ZINC000096937557 |
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | + |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | - |
| Cyp2c9 inhibition | + |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | + |
| Cyp1a2 inhibition | - |
| Oatp2b1 inhibitor | - |
| Oatp1b1 inhibitor | + |
| Oatp1b3 inhibitor | + |
| Mate1 inhibitor | - |
| Oct2 inhibitor | + |
| Bsep inhibitor | + |
| Acute oral toxicity | + |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 1.018 |
| Pharmacokinetic Properties | |
|---|---|
| Number of aromatic heavy atoms | 21 |
| Fraction csp3 | 0.38 |
| Ilogp | 4.83 |
| Xlogp3 | 7.09 |
| Wlogp | 6.07 |
| Mlogp | 5.01 |
| Silicos-it log p | 5.15 |
| Consensus log p | 5.63 |
| Esol log s | -7.66 |
| Esol solubility (mg/ml) | 0.000012 |
| Esol solubility (mol/l) | 2.19E-08 |
| Esol class | Poorly sol |
| Ali log s | -8.5 |
| Ali solubility (mg/ml) | 0.00000172 |
| Ali solubility (mol/l) | 3.14E-09 |
| Ali class | Poorly sol |
| Silicos-it logsw | -9.43 |
| Silicos-it solubility (mg/ml) | 0.0000002 |
| Silicos-it solubility (mol/l) | 3.75E-10 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -4.62 |
| Lipinski number of violations | 2 |
| Ghose number of violations | 3 |
| Veber number of violations | 0 |
| Egan number of violations | 1 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.17 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 2 |
| Synthetic accessibility | 3.76 |
| Pharmacokinetic Properties | |
|---|---|
| Logs | -6.351 |
| Logd | 4.556 |
| Logp | 5.929 |
| F (20%) | 0.003 |
| F (30%) | 0.166 |
| Mdck | 1.52E-05 |
| Ppb | 0.9718 |
| Vdss | 1.776 |
| Fu | 0.02 |
| Cyp1a2-inh | 0.343 |
| Cyp1a2-sub | 0.32 |
| Cyp2c19-inh | 0.856 |
| Cyp2c19-sub | 0.087 |
| Cl | 3.959 |
| T12 | 0.045 |
| H-ht | 0.905 |
| Dili | 0.937 |
| Roa | 0.979 |
| Fdamdd | 0.943 |
| Skinsen | 0.243 |
| Ec | 0.003 |
| Ei | 0.009 |
| Respiratory | 0.713 |
| Bcf | 1.934 |
| Igc50 | 4.919 |
| Lc50 | 5.387 |
| Lc50dm | 5.492 |
| Nr-ar | 0.017 |
| Nr-ar-lbd | 0.01 |
| Nr-ahr | 0.802 |
| Nr-aromatase | 0.933 |
| Nr-er | 0.55 |
| Nr-er-lbd | 0.021 |
| Nr-ppar-gamma | 0.884 |
| Sr-are | 0.896 |
| Sr-atad5 | 0.619 |
| Sr-hse | 0.776 |
| Sr-mmp | 0.742 |
| Sr-p53 | 0.93 |
| Vol | 534.993 |
| Dense | 1.025 |
| Flex | 0.206 |
| Nstereo | 0 |
| Nongenotoxic carcinogenicity | 1 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 1 |
| Surechembl | 0 |
| Nonbiodegradable | 1 |
| Skin sensitization | 0 |
| Acute aquatic toxicity | 1 |
| Toxicophores | 2 |
| Qed | 0.299 |
| Synth | 2.638 |
| Fsp3 | 0.379 |
| Mce-18 | 77.5 |
| Natural product-likeness | -1.552 |
| Alarm nmr | 0 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | 1 |
| Gsk | Rejected |
| Goldentriangle | Rejected |